Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Crown Holdings (CCK) trades near $100 after a modest pullback. With nearly $1.0B in free cash flow, a 35% dividend hike, and an EV/EBITDA of ~8x, the risk-reward favours a long. This trade targets a re-rating to $120 over the next 180 trading days, with a protective stop at $92.
IREN is a vertically integrated, renewable-powered data center platform that just closed multi-billion dollar AI contracts and targeted acquisitions. The stock sold off after a $2bn convertible note offering, creating a long entry at $55.63. If execution on capacity build, enterprise deals and software stack integration go to plan, ARR could scale …
Arvinas, Inc. announced FDA approval of VEPPANU™ (vepdegestrant), the first PROTAC therapy approved for treating ESR1-mutated, ER+/HER2- advanced breast cancer, marking a milestone for the company and the PROTAC modality. The company reported strong clinical progress in its pipeline including positive Phase 1 data for ARV-102 in Parkinson’s disease…
Achieve Life Sciences announced key senior appointments to its board and commercial team, including executives from Verona Pharma, signaling a strong push towards commercializing cytisinicline, a novel treatment for nicotine dependence with FDA review anticipated in June 2026. These leadership additions come shortly after a substantial $354 million…
NeurAxis, Inc. reported a record first quarter for 2026 with revenues up 80% year-over-year to $1.6 million driven by the implementation of the Category I CPT code for their IB-Stim device. The company expanded gross margin and reduced operating losses while securing significant regulatory and commercial milestones including Veterans Affairs contra…
Unicycive Therapeutics announced its first quarter 2026 financial results alongside an optimistic update on the FDA review process for oxylanthanum carbonate (OLC), a novel phosphate binder targeting hyperphosphatemia in chronic kidney disease dialysis patients. The company highlighted its preparedness for a potential product launch following a Jun…
Semiconductor shares slid after a senior South Korean official suggested distributing a 'citizen dividend' funded by taxes on AI profits. The initial reaction sent the Kospi tumbling as much as 5.1%, wiping out over $300 billion in market value before officials moved to clarify the remarks. Major chipmakers including Samsung Electronics, SK Hynix, …
CorVel Corporation will host a live webcast on May 20, 2026, to discuss its quarterly and fiscal earnings, featuring its CEO and CFO. The webcast will include insights into financial performance, strategic initiatives, and a Q&A session. The company highlights its focus on technology-driven risk management solutions in healthcare-related sectors.
Prelude Therapeutics reported Q1 2026 financial results highlighting progress in its oncology pipeline including initiation of a Phase 1 study for PRT12396, a mutant-selective JAK2V617F inhibitor, advancement of PRT13722, a selective oral KAT6A degrader for ER+ breast cancer, and development of novel degrader antibody conjugates. The company extend…
Cartesian Therapeutics, a late-stage clinical biotechnology company focused on cell therapy for autoimmune diseases, announced it will participate in a fireside chat at the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference. The company will discuss its lead CAR-T therapy asset, Descartes-08, currently in various clinical trial phas…
Acumen Pharmaceuticals reported its Q1 2026 financial results and business highlights, emphasizing ongoing progress in its Phase 2 ALTITUDE-AD study for sabirnetug (ACU193), a novel Alzheimer's treatment targeting toxic amyloid beta oligomers. The company expects topline results by late 2026 and plans for an IND filing mid-2027 for its enhanced bra…
C4 Therapeutics reported progress in developing cemsidomide as a foundational multiple myeloma treatment, initiated multiple clinical trials, and expanded its partnership with Roche to develop degrader-antibody conjugates. The company maintains a strong cash position with a runway to the end of 2028, despite a net loss in Q1 2026. Upcoming trial da…
eToro Group Ltd. announced its first quarter 2026 results showing solid financial growth with net contribution rising 19% year-over-year to $258 million and net income up 37% to $82 million. The company expanded product offerings including 24/7 trading for commodities and equities, AI-powered tools, and launched crypto trading in New York. The acqu…
Cal-Maine Foods, Inc., the largest U.S. egg producer, announced the acquisition of the Van's Foods brand from Sara Lee Frozen Bakery. This strategic purchase aims to diversify Cal-Maine's portfolio by entering the better-for-you frozen breakfast segment, expanding prepared foods sales by an estimated 10% annually, and enhancing distribution across …
Colliers International’s U.S. Engineering division is partnering with Oklahoma City-based engineering firm Frankfurt-Short-Bruza Associates (FSB) to establish a national aviation practice and enhance capabilities in federal, mission-critical, and Native American sectors. The partnership will allow Colliers Engineering to access the high-barrier avi…
Olema Pharmaceuticals reported Q1 2026 financials and operational progress, emphasizing upcoming Phase 3 trial results for palazestrant (OPERA-01) expected in fall 2026 and ongoing enrollment in OPERA-02. The company also highlighted initial clinical data for OP-3136 to be presented at ASCO. With over $505 million in cash and expanding clinical pro…
Lantronix Inc. has introduced the xPico 600 series, a production-ready embedded gateway module featuring dual-band Wi-Fi 6, Bluetooth Low Energy 5.4, enterprise-grade security, and integration with their Percepxion cloud platform for zero-touch provisioning and remote device management. Designed to accelerate IoT product development and simplify de…
Seres Therapeutics, a clinical-stage biotechnology company focused on live biotherapeutics, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference, where it will present a company overview. The company is advancing several therapies, including SER-155 and SER-603, targeting inflammatory and immune diseases.
American Shared Hospital Services (AMS), a U.S.-based provider of advanced cancer treatment equipment and services through leasing and patient care segments, announced its first quarter 2026 financial results will be released ahead of a May 14th conference call. The company outlined plans to discuss growth and expansion in Gamma Knife, proton thera…
Applied Optoelectronics Inc. (AAOI) announced a partnership with Mediacom to enhance and expand Mediacom's fiber and coax network infrastructure through the deployment of DOCSIS 4.0 technology. AOI will supply key smart amplifiers and related products to increase network capacity, signal quality, and overall reliability. Mediacom aims to upgrade it…
Opus Genetics announced its financial results for Q1 2026 and provided updates on its gene therapy pipeline targeting inherited retinal diseases (IRDs). The company highlighted ongoing clinical trials, expected data readouts for its OPGx-BEST1 program, FDA acceptance of the LCA5 program into the Rare Disease Evidence Principles program, and plans t…
Tilray Brands' craft brewing division Blue Point Brewing has launched a new year-round IPA called Magic Hour IPA, featuring bright, tropical hop flavors with a 6% ABV. The brew is designed to capture the essence of golden hour relaxation and broaden Blue Point's offering to appeal to both IPA enthusiasts and casual beer drinkers. Magic Hour IPA is …
Broadwind's Q1 2026 results show a slight net loss but strong revenue growth and order increases in gearing and industrial solutions segments. The company announced the sale of its Abilene facility and exiting the wind tower production to focus on higher-growth, more profitable core businesses, improving quality of earnings and liquidity through a …
NovaBridge Biosciences announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company will discuss its innovative biotechnology platform and progress on key pipeline assets including givastomig and VIS-101, which address cancer and retinal vascular diseases respectively. The presentation fo…
Sionna Therapeutics announced the completion of enrollment in its Phase 2a trial evaluating SION-719 for cystic fibrosis, with topline data expected in summer 2026. Additionally, a Phase 1 trial testing combinations involving SION-451 is progressing on schedule. The company maintains a strong cash position of $289.9 million expected to fund operati…
